Dermira Inc. announced key executive appointments with Andrew Guggenhime as Chief Operating Officer and Chief Financial Officer, Christine Conroy as Senior Vice President, Regulatory Affairs and Christine Ring as Vice President, Legal. In addition, Dermira has expanded its board of directors with the appointments of Dr. David E. Cohen, Matthew Fust, Mark McDade and William Ringo. Management Additions: Andrew Guggenhime, Chief Operating Officer and Chief Financial Officer, oversees Dermira's financial, corporate development, human resources, legal, and other administrative functions.

Prior to joining Dermira, Andrew served as Chief Financial Officer for CardioDx. Christine Conroy, Senior Vice President of Regulatory Affairs, is responsible for Dermira's regulatory affairs strategy and function. Christine previously served as Senior Vice President of Regulatory Affairs and Quality Assurance at Affymax.

Christine Ring, Vice President, Legal, is responsible for the company's legal activities. Prior to joining Dermira, Christine most recently served as Chief Intellectual Property Counsel and Senior Vice President, Technology Strategy & Licensing at Amyris. Board of Director Additions: Dr. David E. Cohen, M.D., M.P.H., previously served as a scientific advisor to the Company since its inception.

David has held a variety of positions at the New York University School of Medicine, including as Chief of Allergy and Contact Dermatitis, Vice Chairman of Clinical Affairs, Director of Occupational and Environmental Dermatology, and the Charles C. and Dorothea E. Harris Professor of Dermatology. Matthew Fust was most recently Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals. Matt also serves as a member of the board of directors of MacroGenics, Sunesis Pharmaceuticals and Ultragenyx Pharmaceutical.

Mark McDade currently serves as Executive Vice President, Established Brands, Solutions and Supply, at UCB S.A., which he joined in April 2008. Mark also serves as a member of the board of directors of Five Prime Therapeutics. William Ringo serves as a senior advisor to Barclays Healthcare Group and as a strategic advisor to Sofinnova Ventures.

Bill also serves as a member of the board of directors of Assembly Biosciences, Immune Design, Mirati Therapeutics and Sangamo Biosciences.